News from indivior plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Aug 16, 2016, 07:01 ET Indivior Announces Positive Top-line Phase 3 Pivotal Study Results for RBP-6000 Buprenorphine Monthly Depot for the Treatment of Opioid Use Disorder

There will be a conference call for analysts and investors, hosted by Shaun Thaxter, Chief Executive Officer and Christian Heidbreder, Chief...


Jul 13, 2016, 07:01 ET Indivior Applauds Congressional Passage of Bipartisan Comprehensive Addiction & Recovery Act of 2016 (CARA)

Indivior PLC (LON: INDV) commends the United States Senate and House of Representatives for their leadership in passing the Comprehensive Addiction & ...


May 20, 2016, 11:29 ET Indivior to Present New Data at ISPOR and ICOO that Assess Implications of Adherence, Healthcare Service Utilization and Costs in Opioid Use Disorder

Indivior PLC (LON: INDV) will unveil new real-world data that assess relapse and Buprenorphine Medication-Assisted Treatment (B-MAT) adherence rates...


Oct 21, 2015, 09:35 ET Indivior Applauds Recent Momentum to Address Opioid Dependence and Overdose Epidemic

Indivior PLC (LON: INDV) is encouraged by recent efforts at the federal, state and local levels of government to expand access to treatment options...


Oct 12, 2015, 08:10 ET Indivior PLC Responds to Court's Decision on Motion to Amend

Indivior PLC (LON: INDV) today announced that the U.S. District Court for the District of Delaware granted the Company's motion to amend its...


Jul 29, 2015, 08:57 ET Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review

Indivior PLC (LON: INDV) today announced that the New Drug Application (NDA) for naloxone nasal spray was accepted and received Priority Review by...


May 05, 2015, 07:00 ET Indivior PLC Announces Positive Top-line Results From Pivotal Phase 3 Trial of RBP-7000 in Schizophrenia

Indivior PLC (LON: INDV) today announced top-line results from its phase 3 clinical trial of RBP-7000, an investigational drug in development for the ...


Dec 23, 2014, 10:15 ET La société INDIVIOR PLC est admise à la cote officielle et à la spéculation sur la Bourse de Londres (LSE)

- CE COMMUNIQUÉ NE DOIT PAS ÊTRE PUBLIÉ, DIFFUSÉ OU DISTRIBUÉ (EN TOTALITÉ OU EN PARTIE) DANS, À DESTINATION OU À PARTIR D'UNE JURIDICTION OÙ CELA...


Dec 23, 2014, 10:15 ET Toelating van INDIVIOR PLC tot de officiële lijst en tot verhandeling op de London Stock Exchange

- NIET BESTEMD VOOR VRIJGAVE, PUBLICATIE OF DISTRIBUTIE (GEHEEL NOCH GEDEELTELIJK) IN, NAAR OF VANUIT ENIGE JURISDICTIE. DIT WEL DOEN VORMT EEN...


Dec 23, 2014, 10:10 ET INDIVIOR PLC é admitida na lista oficial para ser negociada na Bolsa de Valores de Londres

- NÃO DEVE SER DIVULGADO, PUBLICADO OU DISTRIBUÍDO (NO TODO OU EM PARTE) EM, DENTRO OU A PARTIR DE NENHUMA JURISDIÇÃO EM QUE SE CONSTITUIRIA UMA...


Dec 23, 2014, 08:31 ET INDIVIOR PLC zum offiziellen Verzeichnis und Handelsverkehr der London Stock Exchange zugelassen

- WEDER TEILWEISE NOCH VOLLUMFÄNGLICH ZUR FREIGABE, PUBLIKATION ODER DISTRIBUTION IN, INNERHALB BZW. AUS RECHTSGEBIETEN BESTIMMT, IN DENEN EINE...


Dec 23, 2014, 06:52 ET INDIVIOR PLC, admitida en el Listado Oficial para cotizar en la Bolsa de Valores de Londres

Indivior PLC (LON: INDV) ("Indivior") empezará a cotizar en el mercado principal de la Bolsa de Valores de Londres a las 8 a.m. GMT del día de hoy a...


Dec 23, 2014, 03:00 ET INDIVIOR PLC Admission to the Official List and to Trading on the London Stock Exchange

Indivior PLC (LON: INDV) ("Indivior") will begin trading on the London Stock Exchange's main market at 8 a.m. GMT today following the admission of...